Literature DB >> 20104242

Device therapy: Defibrillators-a shocking therapy for cardiomyopathy?

John G F Cleland, Laszlo Buga.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20104242     DOI： 10.1038/nrcardio.2009.233

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

Review 1.  Clinical use of intracardiac impedance: current applications and future perspectives.

Authors:  W Arthur; G C Kaye
Journal:  Pacing Clin Electrophysiol       Date:  2001-04       Impact factor: 1.976

2.  The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.

Authors:  Guiqing Yao; Nick Freemantle; Melanie J Calvert; Stirling Bryan; Jean-Claude Daubert; John G F Cleland
Journal:  Eur Heart J       Date:  2006-11-16       Impact factor: 29.983

3.  Cardiac resynchronization therapy: are modern myths preventing appropriate use?

Authors:  John G F Cleland; Luigi Tavazzi; Jean-Claude Daubert; Ahmed Tageldien; Nick Freemantle
Journal:  J Am Coll Cardiol       Date:  2009-02-17       Impact factor: 24.094

4.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

Review 5.  Cardiac resynchronization therapy or atrio-biventricular pacing-what should it be called?

Authors:  John G F Cleland; Mansour Nasir; Ahmed Tageldien
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2007-02

6.  Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.

Authors:  Stuart J Connolly; Paul Dorian; Robin S Roberts; Michael Gent; Steven Bailin; Eric S Fain; Kevin Thorpe; Jean Champagne; Mario Talajic; Benoit Coutu; Gerian C Gronefeld; Stefan H Hohnloser
Journal:  JAMA       Date:  2006-01-11       Impact factor: 56.272

7.  Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results.

Authors:  Mark S Wathen; Paul J DeGroot; Michael O Sweeney; Alice J Stark; Mary F Otterness; Wayne O Adkisson; Robert C Canby; Koroush Khalighi; Christian Machado; Donald S Rubenstein; Kent J Volosin
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

8.  A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial.

Authors:  Bruce L Wilkoff; Kevin T Ousdigian; Laurence D Sterns; Zengri J Wang; Ryan D Wilson; John M Morgan
Journal:  J Am Coll Cardiol       Date:  2006-06-22       Impact factor: 24.094

9.  A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection window programming in patients with LEft VentriculAr dysfunction, Non-ischemic eTiology in primary prevention treated with a biventricular ICD] study.

Authors:  Maurizio Gasparini; Carlo Menozzi; Alessandro Proclemer; Maurizio Landolina; Severio Iacopino; Angelo Carboni; Ernesto Lombardo; François Regoli; Mauro Biffi; Valeria Burrone; Alessandra Denaro; Giuseppe Boriani
Journal:  Eur Heart J       Date:  2009-06-29       Impact factor: 29.983

10.  Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.

Authors:  Bruce L Wilkoff; Brian D Williamson; Richard S Stern; Stephen L Moore; Fei Lu; Sung W Lee; Ulrika M Birgersdotter-Green; Mark S Wathen; Isabelle C Van Gelder; Brooke M Heubner; Mark L Brown; Keith K Holloman
Journal:  J Am Coll Cardiol       Date:  2008-08-12       Impact factor: 24.094
  10 in total
  4 in total

1.  Increasing knowledge and changing views in cardiac resynchronization therapy.

Authors:  Laszlo Buga; John G F Cleland
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214

2.  Cardiac resynchronization therapy update: evolving indications, expanding benefit?

Authors:  C Butcher; Y Mareev; V Markides; M Mason; T Wong; J G F Cleland
Journal:  Curr Cardiol Rep       Date:  2015-10       Impact factor: 2.931

Review 3.  How to improve outcomes: should we put more emphasis on programming and medical care and less on patient selection?

Authors:  Laszlo Buga
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214

Review 4.  The determinants of clinical outcome and clinical response to CRT are not the same.

Authors:  John G F Cleland; Stefano Ghio
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.